Premium
End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T‐cell acute lymphoblastic leukemia
Author(s) -
Parekh Chintan,
Gay Paul S.,
AbdelAzim Hisham
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25582
Subject(s) - minimal residual disease , medicine , induction therapy , lymphoblastic leukemia , oncology , complete remission , pediatric oncology , flow cytometry , leukemia , disease , stem cell , haematopoiesis , pediatrics , immunology , chemotherapy , cancer , biology , genetics
The role of end of induction minimal residual disease (MRD) as determined by flow cytometry for treatment assignment in pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) is not well defined. We studied 33 children with newly diagnosed T‐ALL. Thirty‐two of 33 patients remain in continuous complete remission at a median of 4 years. Nineteen patients were MRD positive at the end of induction and all remain in remission with augmented Berlin Frankfurt Münster‐based therapy. One patient underwent hematopoietic stem cell transplant for rising MRD. Persistent end of induction MRD alone is not an indication to alter therapy in pediatric T‐ALL. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.